Company Filing History:
Years Active: 1990
Title: Martin Bard: Innovator in Genetic Engineering
Introduction
Martin Bard is a notable inventor based in Menomonee Falls, Wisconsin. He has made significant contributions to the field of genetic engineering, particularly in the area of recombinant DNA technology. His work has implications for agricultural biotechnology and herbicide development.
Latest Patents
Martin Bard holds a patent for a novel DNA for the expression of delta-aminolevulinic acid synthetase. This invention presents a method for maintaining and selecting recombinant DNA-containing host cells. The DNA encoding a selectable phenotype and the DNA encoding a useful polypeptide are the same. This DNA is particularly useful for expressing delta-aminolevulinic acid synthetase (ALAS) for the ultimate expression of delta-aminolevulinic acid (ALA) in yeast and related organisms. The invention also includes plasmids pIT300, pIT301, pIT302, pIT304, pIT305, pIT306, and related Saccharomyces ALA deficient transformants. ALA is a five-carbon amino acid that serves as a light-dependent herbicide.
Career Highlights
Martin Bard is associated with Eli Lilly and Company, where he has been able to apply his innovative ideas in a corporate setting. His work has contributed to advancements in biotechnology and has the potential to impact agricultural practices.
Collaborations
Martin has collaborated with Thomas D Ingolia, further enhancing the scope and impact of his research in the field of genetic engineering.
Conclusion
Martin Bard's contributions to genetic engineering through his innovative patent demonstrate the importance of research and development in biotechnology. His work continues to influence the agricultural sector and showcases the potential of recombinant DNA technology.